Abstract
The landscape of acute lymphoblastic leukemia (ALL) treatment is rapidly evolving, with new therapies challenging traditional treatment paradigms. While allogeneic hematopoietic cell transplantation (allo-HCT) remains essential for many high-risk patients, advances in measurable residual disease (MRD) monitoring and the increasing use of immunotherapies in earlier treatment lines have reshaped transplant decision-making. Improvements in donor availability, conditioning strategies, and post-transplant care have expanded access and improved survival, yet relapse and toxicity remain major challenges. This review examines the evolving role of allo-HCT in ALL, highlighting key advancements and ongoing challenges.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 689-697 |
| Number of pages | 9 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 25 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 2025 |
Keywords
- Allogeneic hematopoietic cell transplantation
- Chimeric antigen receptor T-cell therapy
- Immunotherapies
- Measurable residual disease
- Risk stratification
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Fingerprint
Dive into the research topics of 'SOHO State of the Art Updates and Next Questions | Transplant in Adult Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS